“ "Our objective moving forward is very clear: continue bringing innovation in all our areas and make ISDIN a strong reference in the Brazilian market." ”
In Conversation
“ "Pediapharm is unique, in that we master the pediatric market in Canada and are able to bring all key stakeholders in the field together and draw… ”
Interview: Leonas Kalėtinas – Executive Director, Lithuanian Innovative Pharmaceutical Industry Association (IFPA)
“ "The market of clinical research is quite small in Lithuania, but the research-based players are being quite active in this front with clinical trial investments at… ”
“ "The central part of the spirit of Debiotech is to have an impact, and not just gain financial revenues." ”
Interview: Predrag Lukic – General Manager Serbia, Regional Director Montenegro, Macedonia, Bosnia and Herzegovina, Kosovo, Amicus
“ "We are still at the beginning of our partnership acquisition and have recognized that the market is stable – even promising." ”
“ "Our country has made huge progress, and I see the recent economic turmoil as an evidence that Brazil is finally tackling long-lasting corruption problems." ”
“ "Poland finds itself in a unique position, and we believe we have the chance to be considered as a hub for cardiovascular activity." ”
“ "We will continue with the following principle: if the product is not as good as we wish, we prefer not to sell it or wait until… ”
“ "All the healthcare stakeholders, even the government, agree that Lithuania should move the reimbursement criteria from purely cost of the drug to value-based healthcare and e-Health… ”
“ "Although we remain relatively small in terms of sales, Brazil has already become a strategic market for Boiron, where some innovative, pilot projects are currently under… ”
“ "For Pharmanova, we would like the face of our brand to be someone well-known, well-respected and an everyday user of our products." ”
Raymond De Vré – Senior Vice-President; Head, Business Operations and Strategy, Biologics, Dr. Reddy’s, Switzerland
“ The main challenge in the mature markets is the stringency of the regulatory frameworks: the sheer amount of clinical, non-clinical and analytical evidence that is required… ”